Carnegie Investment Counsel’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Carnegie Investment Counsel’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.87M	Sell	37,121 -12,776	-26%	-$1.73M	0.12%	155
2026 Q1	$6.37M	Sell	49,897 -601	-1%	-$75K	0.12%	162
2025 Q4	$6.16M	Sell	50,498 -291	-0.6%	-$33.4K	0.11%	163
2025 Q3	$5.09M	Buy	50,789 +1,174	+2%	+$106K	0.1%	175
2025 Q2	$4.11M	Sell	49,615 -1,830	-4%	-$146K	0.08%	183
2025 Q1	$3.76M	Sell	51,445 -49,661	-49%	-$4.44M	0.09%	175
2024 Q4	$9.11M	Buy	101,106 +5,683	+6%	+$551K	0.26%	103
2024 Q3	$9.43M	Buy	95,423 +2,975	+3%	+$292K	0.28%	97
2024 Q2	$8.57M	Buy	92,448 +9,055	+11%	+$812K	0.27%	99
2024 Q1	$7.91M	Buy	83,393 +20,282	+32%	+$1.88M	0.25%	103
2023 Q4	$5.64M	Sell	63,111 -34,429	-35%	-$2.56M	0.19%	125
2023 Q3	$7.12M	Sell	97,540 -4,067	-4%	-$325K	0.27%	98
2023 Q2	$8.45M	Buy	101,607 +6,075	+6%	+$508K	0.31%	93
2023 Q1	$7.28M	Sell	95,532 -1,627	-2%	-$135K	0.29%	98
2022 Q4	$8.06M	Buy	97,159 +2,109	+2%	+$171K	0.35%	81
2022 Q3	$7.54M	Buy	95,050 +11,767	+14%	+$992K	0.36%	81
2022 Q2	$6.18M	Sell	83,283 -29,403	-26%	-$2.21M	0.28%	99
2022 Q1	$10.1M	Buy	112,686 +19,050	+20%	+$1.76M	0.37%	81
2021 Q4	$10.5M	Sell	93,636 -16,368	-15%	-$1.97M	0.35%	88
2021 Q3	$13.8M	Buy	110,004 +6,973	+7%	+$898K	0.52%	64
2021 Q2	$13.9M	Buy	103,031 +18,083	+21%	+$2.38M	0.53%	62
2021 Q1	$11.5M	Buy	84,948 +7,813	+10%	+$1.17M	0.48%	67
2020 Q4	$10.9M	Buy	77,135 +1,601	+2%	+$205K	0.49%	66
2020 Q3	$8.42M	Buy	75,534 +190	+0.3%	+$21.3K	0.43%	71
2020 Q2	$8.43M	Buy	75,344 +1,943	+3%	+$191K	0.48%	61
2020 Q1	$5.68M	Sell	73,401 -27,300	-27%	-$2.42M	0.39%	76
2019 Q4	$9.58M	Buy	100,701 +153	+0.2%	+$13.2K	0.55%	54
2019 Q3	$7.67M	Sell	100,548 -5,124	-5%	-$426K	0.49%	63
2019 Q2	$9.27M	Buy	105,672 +6,617	+7%	+$564K	0.6%	47
2019 Q1	$8.97M	Buy	99,055 +2,717	+3%	+$231K	0.62%	48
2018 Q4	$6.91M	Sell	96,338 -42,221	-30%	-$3.4M	0.64%	42
2018 Q3	$11.1M	Buy	138,559 +39,031	+39%	+$3.78M	0.91%	31
2018 Q2	$9.44M	Buy	99,528 +2,233	+2%	+$205K	0.72%	42
2018 Q1	$8.92M	Buy	97,295 +1,906	+2%	+$174K	0.75%	41
2017 Q4	$8.72M	Buy	95,389 +4,313	+5%	+$361K	0.77%	36
2017 Q3	$7.69M	Buy	91,076 +2,021	+2%	+$162K	0.9%	29
2017 Q2	$6.87M	Buy	89,055 +4,194	+5%	+$297K	0.84%	33
2017 Q1	$5.87M	Buy	84,861 +3,196	+4%	+$215K	0.73%	44
2016 Q4	$5.1M	Buy	81,665 +49,830	+157%	+$3.08M	0.68%	50
2016 Q3	$1.88M	Buy	31,835 +25,340	+390%	+$1.57M	0.27%	104
2016 Q2	$400K	Buy	+6,495	New	+$356K	0.06%	240
2014 Q2	–	Sell	-8,259	Closed	-$392K	–	233
2014 Q1	$392K	Sell	8,259 -57,822	-88%	-$2.96M	0.1%	158
2013 Q4	$2.87M	Buy	66,081 +2,880	+5%	+$119K	0.77%	49
2013 Q3	$2.72M	Sell	63,201 -3,738	-6%	-$151K	0.84%	39
2013 Q2	$2.33M	Buy	+66,939	New	+$2.35M	0.76%	47

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

Carnegie Investment Counsel's XBI Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 26% in Q2 2026, selling an estimated $1.73M and leaving 37,121 shares worth $5.87M. The position accounts for 0.12% of the portfolio, ranked #155.

Carnegie Investment Counsel first reported a position in XBI in Q2 2013 and has held it in 45 quarters since. The position peaked at $13.9M in Q2 2021. 551 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Carnegie Investment Counsel held 37,121 shares of State Street SPDR S&P Biotech ETF worth $5.87M as of Q2 2026.
Carnegie Investment Counsel sold 12,776 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.73M.
State Street SPDR S&P Biotech ETF made up 0.12% of Carnegie Investment Counsel's portfolio in Q2 2026, its #155 holding.
Carnegie Investment Counsel first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 45 quarters since.
Carnegie Investment Counsel's State Street SPDR S&P Biotech ETF position peaked at $13.9M in Q2 2021.
551 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.